Abstracts tagged "Biomarkers"

Abstract Number: 75 • 2017 ACR/ARHP Annual Meeting
Factors Associated with TNF Receptor 2 Levels Above the Measurable Range in Rheumatoid Arthritis
Michelle Frits¹, Gary Bradwin², Nancy A. Shadick¹, Christine Iannaccone³, Michael Weinblatt¹, Nader Rifai² and Katherine P. Liao⁴, ¹Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Laboratory Medicine, Childrens Hospital Boston, Boston, MA, ³Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁴Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Tumor necrosis factor-alpha (TNFa) is involved in the pathogenesis of RA and is increasingly being studied as a biomarker of cardiovascular disease (CVD). While…
Abstract Number: 668 • 2017 ACR/ARHP Annual Meeting
Is Uric Acid Level a Predictor of Long-Term Renal Outcome in Lupus Nephritis?
Michelle Lopes¹, Samara Gavinier², Elaine Leon², Vilma Viana², Eduardo Ferreira Borba¹ and Eloisa Bonfa³, ¹Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR, São Paulo, Brazil, ³Rheumatology Divison, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Hyperuricemia has been reported to be associated with chronic kidney disease (CKD) in several clinical conditions, and recent studies also observed an association between…
Abstract Number: 867 • 2017 ACR/ARHP Annual Meeting
Highly Sensitive Cardiac Troponin-I in Peripheral Blood Predicts Cardiovascular Events in Patients with Rheumatoid Arthritis
George Karpouzas¹, Joel Estis², Long Pham³, John Todd² and Matthew Budoff⁴, ¹Division of Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, ²Singulex, Alameda, California, Alameda, CA, ³Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, ⁴Cardiology, Harbor-UCLA Medical Center, Torrance, CA
Background/Purpose: Cardiac troponins (cTn) are specific biomarkers of myocardial injury; their measurement with highly-sensitive assays and at subthreshold levels for myocardial infarction (MI) diagnosis, predicts…
Abstract Number: 1399 • 2017 ACR/ARHP Annual Meeting
Tissues Are Differently Modulated By Tocilizumab and Methotrexate; Assessment of Connective Tissue Metabolites in the Ambition Study
Anne C. Bay-Jensen¹, Anne Sofie Siebuhr¹, Christian S. Thudium² and Morten Asser Karsdal¹, ¹Rheumatology, Nordic Bioscience, Herlev, Denmark, ²Biomarkers and Research, Nordic Bioscience, Herlev, Denmark
Background/Purpose: The response to any treatment in rheumatoid arthritis (RA) is assessed by symptomatic changes, such as swollen joint count and DAS28. However, such assessments…
Abstract Number: 2075 • 2017 ACR/ARHP Annual Meeting
The Effect of Uric Acid Lowering Treatment on the Microbiome in Gout Patients
Hye Won Kim¹, Eun-Jeong Yoon², Seok Hoon Jeong² and Min-Chan Park¹, ¹Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine,Gangnam Severance Hospital, Seoul, Korea, Republic of (South), ²Department of Laboratory Medicine, Severance Hospital, Research Institute of Bacterial Resistance, Yonsei University College of Medicine, Seoul, Korea, Republic of (South)
Background/Purpose: Accumulating evidence indicates that gut microbiota interact with gout but it is still unknown how the uric acid lowering treatment (ULT) affects to the…
Abstract Number: 2858 • 2017 ACR/ARHP Annual Meeting
Validation of Biomarkers to Predict Flare in Polyarticular JIA upon Stopping Anti-TNF Therapy
Daniel J Lovell¹, Sarah Ringold² and P. Scott Eastman³, ¹PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Seattle Children's Hospital, Seattle, WA, ³Senior Director, New Product Development, Crescendo Bioscience, South San Francisco, CA
Background/Purpose: More than 40% of children with polyarticular forms of Juvenile Idiopathic Arthritis (JIA) experience clinical inactive disease on medication (CR). No clinical variable or…
Abstract Number: 78 • 2017 ACR/ARHP Annual Meeting
IL-37 Is Associated with Increased Atherogenesis in Patients with Rheumatoid Arthritis
Barbora Sumova^1,2, Tereza Lennerova^1,2, Lucie Andres Cerezo¹, Hana Hulejova¹, Romana Jandova¹, Karel Pavelka^1,2, Jiri Vencovsky^1,2 and Ladislav Senolt^1,2, ¹Institute of Rheumatology, Prague, Czech Republic, Prague, Czech Republic, ²Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: Interleukin-37 (IL-37) is one of few anti-inflammatory cytokines belonging to the IL-1 cytokine family. It is mainly produced by immune cells of innate immunity…
Abstract Number: 674 • 2017 ACR/ARHP Annual Meeting
Identification of IRAK4-Dependent Gene Signature As a Biomarker Candidate for IRAK4 Small-Molecule Inhibitor in Systemic Lupus Erythematosus
A. Francesca Setiadi¹, Kate Senger¹, Jason Hackney², Neta Zuckerman¹, Swathi Sujatha-Bhaskar¹, George Francis¹, Marian Bryan¹, Hans Brightbill¹, Ali A. Zarrin¹ and Michael J. Townsend¹, ¹Genentech, South San Francisco, CA, ²Bioinformatics and Computational Biology, Genentech, South San Francisco, CA
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a heterogeneous disease. Interleukin-1 receptor-associated kinase 4 (IRAK4) activity is predicted to affect multiple pathogenic pathways in SLE1. We…
Abstract Number: 940 • 2017 ACR/ARHP Annual Meeting
IL1RN Variation Is Associated with Systemic Juvenile Idiopathic Arthritis and Predicts Non-Response to Anakinra Treatment
Emily Shuldiner¹, Victoria Arthur¹, Anne Hinks², Patricia Woo³, Wendy Thomson², Elaine F. Remmers⁴ and Michael J. Ombrello¹, ¹Translational Genetics and Genomics Unit, NIAMS, NIH, Bethesda, MD, ²Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, United Kingdom, ³University College London, London, United Kingdom, ⁴Genetics and Genomics Branch, NIH, NIAMS, Bethesda, MD
Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is a childhood inflammatory disease whose pathophysiology is poorly understood. sJIA is phenotypically heterogeneous with variable manifestations and responses…
Abstract Number: 1416 • 2017 ACR/ARHP Annual Meeting
Higher Expression of Type 1 Interferon in Synovitis of Patient with Undifferentiated Arthritis before They Met Rheumatoid Arthritis Criteria Compared to Established Rheumatoid Arthritis. a Retrospective Study with 14 Years of Follow-up
Andrea Cuervo¹, Raquel Celis², Julio Ramírez³, Alicia Usategui⁴, Regina Faré⁵, M. Victoria Hernández⁶, Virginia Ruiz-Esquide³, Jose Inciarte-Mundo⁷, Raimon Sanmarti⁸, Jose L. Pablos⁹ and Juan D. Cañete⁷, ¹Arthritis Unit. Rheumatology Dpt, Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona and IDIBAPS, Barcelona, Spain, ²Arthritis Unit, Rheumatology Department, Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona and IDIBAPS, Barcelona, Spain, ³Rheumatology Service, Hospital Clínic de Barcelona, Barcelona, Spain, ⁴Grupo de Enfermedades Inflamatorias y Autoinmunes, Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain, ⁵Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain, ⁶Hospital Clinic. Barcelona. Spain, Barcelona, Spain, ⁷Rheumatology Department, Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona, Barcelona, Spain, ⁸Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona, Barcelona, Spain, ⁹Servicio de Reumatología, Hospital 12 de Octubre, Madrid, Spain
Background/Purpose: Undifferentiated Arthritis (UA) is defined as an inflammatory oligo/poly arthritis that does not fulfil criteria for a definitive diagnosis.Delay in diagnosis and treatment leads…
Abstract Number: 2176 • 2017 ACR/ARHP Annual Meeting
Clusterin Is Upregulated in Muscle Tissue and Serum in Idiopathic Inflammatory Myopathies and Is Associated with Clinical Disease Activity
Tereza Lennerova^1,2, Lucia Vernerova¹, Martin Klein¹, Veronika Hruskova^1,3, Lucie Andres Cerezo¹, Barbora Sumova^1,2, Michal Tomcik^1,2, Sabina Oreska^1,2, Herman F Mann^1,2, Josef Zamecnik⁴, Karel Pavelka^1,2, Jiri Vencovsky^1,2 and Ladislav Senolt^1,2, ¹Institute of Rheumatology, Prague, Czech Republic, Prague, Czech Republic, ²Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ³Faculty of Science, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁴Department of Pathology and Molecular Medicine, 2nd Medical School and University Hospital Motol, Charles University, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: Clusterin (also known as apolipoprotein J) is a molecular chaperone that participates in a number of biological processes, such as inflammation and apoptosis. Recent…
Abstract Number: 2863 • 2017 ACR/ARHP Annual Meeting
Serum Proteomic Signatures Predict Relapse in Rheumatoid Arthritis Patients Undergoing DMARD Withdrawal
Liam O'Neil¹, Victor Spicer², Carol A Hitchon², Juergen Rech³, Axel J. Hueber⁴, John Wilkins², Hani El-Gabalawy¹ and Georg Schett³, ¹Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ²University of Manitoba, Winnipeg, MB, Canada, ³Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Erlangen, Germany., Erlangen, Germany, ⁴Department of Medicine 3, Rheumatology and Immunology, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: Early and targeted treatment strategies have led to increasing numbers of patients with RA achieving sustained clinical remission. If and when to taper Disease…
Abstract Number: 129 • 2017 ACR/ARHP Annual Meeting
Impact of the Multi-Biomarker Disease Activity Score Results on Whether Rheumatologists Changed Biologic Therapy for RA Patients
Jeffrey R. Curtis¹, Kerri Ford², Lang Chen³, Huifeng Yun³ and Fenglong Xie⁴, ¹Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ²Crescendo Bioscience Inc., South San Francisco, CA, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The multi-biomarker disease activity (MBDA) score is a validated test used to assess disease activity for patients with rheumatoid arthritis (RA). How it is…
Abstract Number: 675 • 2017 ACR/ARHP Annual Meeting
Tissue-Based Biomarkers in Cutaneous Lupus Erythematosus: Type I IFN Responsive Protein Mxa and a Marker for Lymphocytic Inflammation (CD45) Correlate with CLASI Cross-Sectionally and Longitudinally
Taylor L. Reynolds¹, Carrie Wager¹, Stefan Hamann¹, Xueli Zhang¹, Galina Marsh¹, Cristina Musselli¹, Nathalie Franchimont¹, Agnes Gardet¹, Robert Dunstan², Dania Rabah¹ and Victoria P Werth³, ¹Biogen, Cambridge, MA, ²Abbvie, Worcester, MA, ³University of Pennsylvania and the VA Medical Center, Philadelphia, PA
Background/Purpose: Cutaneous lupus erythematosus (CLE) is the cutaneous manifestation of SLE, affecting 85% of patients1. CLE is subdivided into acute, subacute and chronic/discoid forms. Discoid…
Abstract Number: 969 • 2017 ACR/ARHP Annual Meeting
Modulation of Cartilage Degradation Biomarkers Reflect the Activation and Inhibition of Pro-Inflammatory Cytokine Signaling in an Ex Vivo Model of Bovine Cartilage
Cecilie F. Kjelgaard-Petersen^1,2, Neha Sharma^1,3, Ashref Kayed^4,5, Britt Christensen¹, Morten Karsdal⁶, Anne-C. Bay-Jensen⁷ and Christian S. Thudium¹, ¹Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ²Bioengineering, Technical University of Denmark, Kgs. Lyngby, Denmark, ³Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark, ⁴Research and Biomarkers, Nordic Bioscience, Herlev, Denmark, ⁵Biomolecular Sciences, University of Copenhagen, Copenhagen, Denmark, ⁶Biomarkers and Reseacrh, Nordic Bioscience, Herlev, Denmark, ⁷Biomarkers and Reseach, Nordic Bioscience, Herlev, Denmark
Background/Purpose: Several inflammatory cytokines and intracellular signaling pathways have been targeted in drug development with varying clinical results. Improved understanding of the intracellular signaling’s modulation…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].